Bluebird Sees Commercial Growth For Gene Therapies, But Cash Remains An Overhang
The biotech anticipates treating 74 patients with its gene therapies this year, with 30 more already scheduled for 2025.
The biotech anticipates treating 74 patients with its gene therapies this year, with 30 more already scheduled for 2025.